TY - JOUR
T1 - A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry
AU - Knapen, L. M.
AU - Geurts, S. M. E.
AU - Ibragimova, K. I. E.
AU - Croes, S.
AU - Vriens, B. E. P. J.
AU - van den Berkmortel, F. W. P. J.
AU - Dercksen, M. W.
AU - van de Wouw, A. J.
AU - Pepels, M. J. A. E.
AU - de Fallois, A. O. J.
AU - Lobbezoo, D. J. A.
AU - de Boer, M.
AU - Tjan-Heijnen, V. C. G.
N1 - Funding Information:
This work was supported by the Netherlands Organization for Health Research and Development (ZonMw: 80-82500-98-8003 ); Novartis BV; Roche; Pfizer.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/4
Y1 - 2019/4
N2 - Purpose: We aimed to assess the implementation and effectiveness of exemestane plus everolimus treatment per hospital type in real-life, shortly after approval of everolimus.Methods: Advanced breast cancer patients treated with exemestane plus everolimus in 2012-2014 were included from the SONABRE registry. Progression-free survival (PFS) and a 12-week conditional PFS (post-hoc) were estimated by Kaplan-Meier method. The multivariable Cox proportional hazards model was performed by type of hospital and adjusted for patient, tumour and treatment characteristics.Results: We included 122 patients, comprising 48 patients treated in academic (N = 1), 56 in teaching (N = 4), and 18 in non-teaching (N = 2) hospitals. The median PFS was 6.3 months (95% Confidence Interval (CI) 4.0-8.6) overall, and 8.5 months (95% CI 7.7-9.3), 4.2 months (95% CI 2.0-6.3), and 5.5 months (95% CI 4.2-6.7) for the patients treated in academic, teaching and non-teaching hospitals, respectively. The adjusted Hazard Ratio (HR) for PFS-events was 1.5 (95% CI 1.0-2.2) and 1.0 (95% CI 0.5-1.9) respectively for patients treated at teaching and non-teaching hospitals versus the academic hospital. The adjusted HR for 12-week conditional PFS-events was not different between hospital types. In the first 12-week treatment period, treatment was discontinued due to early progression in one out of 48 patients in the academic versus nine out of 74 patients in the non-academic hospitals, confirmed by imaging in one and two patients, respectively.Conclusions: In our study, the median PFS was borderline significantly different between hospital types, possibly the result of a different assessment approach in the first 12-week treatment period. (C) 2019 Elsevier Ltd. All rights reserved.
AB - Purpose: We aimed to assess the implementation and effectiveness of exemestane plus everolimus treatment per hospital type in real-life, shortly after approval of everolimus.Methods: Advanced breast cancer patients treated with exemestane plus everolimus in 2012-2014 were included from the SONABRE registry. Progression-free survival (PFS) and a 12-week conditional PFS (post-hoc) were estimated by Kaplan-Meier method. The multivariable Cox proportional hazards model was performed by type of hospital and adjusted for patient, tumour and treatment characteristics.Results: We included 122 patients, comprising 48 patients treated in academic (N = 1), 56 in teaching (N = 4), and 18 in non-teaching (N = 2) hospitals. The median PFS was 6.3 months (95% Confidence Interval (CI) 4.0-8.6) overall, and 8.5 months (95% CI 7.7-9.3), 4.2 months (95% CI 2.0-6.3), and 5.5 months (95% CI 4.2-6.7) for the patients treated in academic, teaching and non-teaching hospitals, respectively. The adjusted Hazard Ratio (HR) for PFS-events was 1.5 (95% CI 1.0-2.2) and 1.0 (95% CI 0.5-1.9) respectively for patients treated at teaching and non-teaching hospitals versus the academic hospital. The adjusted HR for 12-week conditional PFS-events was not different between hospital types. In the first 12-week treatment period, treatment was discontinued due to early progression in one out of 48 patients in the academic versus nine out of 74 patients in the non-academic hospitals, confirmed by imaging in one and two patients, respectively.Conclusions: In our study, the median PFS was borderline significantly different between hospital types, possibly the result of a different assessment approach in the first 12-week treatment period. (C) 2019 Elsevier Ltd. All rights reserved.
KW - Advanced breast cancer
KW - Metastatic breast cancer
KW - Everolimus
KW - Hormone-receptor-positive
KW - Real life
KW - Progression-free survival
KW - AROMATASE INHIBITORS
KW - TRIAL
KW - CHEMOTHERAPY
KW - MULTICENTER
KW - EFFICACY
KW - THERAPY
KW - SAFETY
U2 - 10.1016/j.breast.2019.01.001
DO - 10.1016/j.breast.2019.01.001
M3 - Article
C2 - 30641299
SN - 0960-9776
VL - 44
SP - 46
EP - 51
JO - Breast
JF - Breast
ER -